What is the 60 Degrees Pharmaceuticals Inc. stock price forecast?

60 Degrees Pharmaceuticals Inc. is currently trading at $1.49. View real-time AI analysis on Alpha Lenz.

What is 60 Degrees Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for 60 Degrees Pharmaceuticals Inc. on Alpha Lenz.

What is 60 Degrees Pharmaceuticals Inc.'s P/E ratio?

60 Degrees Pharmaceuticals Inc.'s P/E ratio is -0.2.

60 Degrees Pharmaceuticals Inc.

NASDAQ · SXTP

$1.49-0.01(-0.67%)Pre-market

Ask about 60 Degrees Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“60 Degrees Pharmaceuticals Inc. trades at a P/E of -0.2 (undervalued) with modest ROE of -196.4%. 3Y revenue CAGR of 65.2% highlights clear growth momentum.”

Ask for details →

Company Overview

60 Degrees Pharmaceuticals Inc. is a biotechnology company that specializes in the discovery, development, and commercialization of treatments for infectious diseases, particularly those impacting travelers and other affected populations. The company is renowned for its focused efforts on addressing tropical diseases, leveraging its expertise to offer solutions where medical needs are unmet, such as malaria prevention. With innovative approaches in pharmaceutical research and development, 60 Degrees Pharmaceuticals Inc. plays a vital role in the pharmaceutical sector, enhancing healthcare outcomes. Its contributions are significant, as it targets diseases prevalent in underserved regions, working towards creating sustainable health solutions globally. The company's focus on bringing advanced health innovations to the market positions it as a key player in addressing global health challenges, while its strategic research initiatives underline its importance in both the biotechnology landscape and global public health efforts.

CEODr. Geoffrey Stuart Dow Ph.D.

Websitehttps://www.60degreespharma.com

SectorHealthcare

IndustryBiotechnology

Employees3

Company Statistics

FY 2025

Profile

$1.73MMarket Cap

$1.01MRevenue

0.00Shares Out

3Employees

Margins

22.26%Gross

-750.27%EBITDA

-771.64%Operating

-732.82%Pre-Tax

-732.82%Net

Valuation

-0.24P/E

0.50P/B

1.72EV/Sales

-0.04EV/EBITDA

-0.25P/FCF

Growth (CAGR)

65.15%Rev 3Yr

-14.35%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-132.46%ROA

-196.44%ROE

-132.32%ROIC

Financial Health

$1.51MCash & Cash Equivalents

$476.73KNet Debt

58.79%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“60 Degrees Pharmaceuticals Inc. trades at a P/E of -0.2 (undervalued) with modest ROE of -196.4%. 3Y revenue CAGR of 65.2% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

60 Degrees Pharmaceuticals Inc. (ticker: SXTP) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 3 employees. Market cap is $2M.

The current price is $1.49 with a P/E ratio of -0.24x and P/B of 0.5x.

ROE is -196.44% and operating margin is -771.64%. Annual revenue is $1M.